

Pipeline Progress™

Pipeline Progress is a revolutionary and unique analytic tool which leverages BioPharm Insight's massive historical database of drug profiles and clinical trial outcomes to quantify the likelihood of an individual drug candidate advancing into its next phase of testing or gaining regulatory approval.

BioPharm Insight provides objective and quantitative Pipeline Progress scores, alongside subjective and qualitative opinions from subject matter experts as captured by independent investigative journalists, to provide you with a complete picture of a drug's clinical outlook.

Pipeline Progress uses a proprietary algorithm to analyze dozens of precise variables from similar prior trials, assigns a numerical score to each drug, and enables you to quickly identify promising candidates and potential warning signs before your competitors. By projecting a drug's approval prospects forward through a number of years, Pipeline Progress also allows you to anticipate trends in how a company's pipeline mix will evolve over time.

Trade Name	Generic Name	Therapeutic Area	Indication	Company	Phase	Probability of Approval
[18F] Flutemetamol	[18f] Flutemetamol	Diagnostic / Imaging Agents / Delivery	Imaging Agents, Other	Ge Healthcare	f. Phase III	91.81%
Mipomersen	Mipomersen	Hematological	Hypercholesterolemia	Genzyme Corporation, a Sanofi Company	f. Phase III	91.06%
Aquavan	Fospropofol Disodium	Pain	Anesthesia	Eisai Co., Ltd.	f. Phase III	90.78%
Inavir	Laninamivir Octanoate	Infectious Diseases	Influenza	Daiichi Sankyo Company, Limited	f. Phase III	89.04%

Drugs searches within or across therapeutic areas can be sorted by phase or company and can either be viewed individually or compared and arranged by probability of approval

Who Benefits from Pipeline Progress?

The ability to reliably forecast drug approval probabilities for the nearly 100,000 drugs in the BioPharm Insight database enables you to take action before your peers:

CROs, CMOs and Service Providers - Proactively anticipate your key clients' future needs and market shifts, and identify historically difficult programs you will be able to help resolve.

Biopharma Companies - Focus on the best candidates for in-licensing, rank and compare competitive compounds and portfolio strategy, and receive email updates as scores change.

Financial Markets Firms - Capitalize on investment opportunities before your peers and more accurately evaluate companies using probability-adjusted expected revenue streams.

Try It Today

Sign up for complimentary trial access to BioPharm Insight at www.biopharminsight.com.